Some biotech companies are offering a new way to soften the shock of drug prices: Insurers pay only if the patient improves.
The rise of spit kits is leaving consumers with lots of data and few answers. Genetic counselors could help people understand these results, but there aren’t enough of them to go around.
A new vaginal incubator is half the price of traditional IVF and could be more acceptable to Catholics. Will it revolutionize access to fertility medicine?
The specter of being removed from the United States has devastating effects on the health of undocumented immigrants and their loved ones.